cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Incretin-based therapies for the treatment of obesity-related diseases Novo Nordisk's CagriSema 2.4 mg
Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 Novo's CagriSema loses phase 3 obesity battle against Zepbound Dual Therapy CagriSema Promising for Weight and Glycaemic Control EMJ New trial data on CagriSema 23% weight loss at 84 weeks in the RE DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows
Pay in 4 interest-free payments of $5.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


